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Abstract
The goal of diabetes mellitus treatment is to maintain long-term near-normoglycaemia to prevent the onset or progression of long-term
complications. In order to achieve tight glycaemic control and improve the quality of life for diabetic patients, a number of novel insulin
preparations, insulin analogues, have been constructed thanks to recombinant DNA technologies and advanced protein chemistry. Be-
cause structurally modified insulins may differ from human insulin not only in metabolic but also in mitogenic potencies there were
concerns raised about the possibility of increased insulin analogue proliferative action or tumourigenesis. In vitro and in vivo studies on
insulin analogues in comparison to endogenous insulin have been performed to closely monitor the insulin analogue action profiles.
Insulin glargine was the only one presenting a significant increase in affinity to insulin-like growth factor type 1 (IGF-1) receptor. Howe-
ver, there was controversy regarding the safety of insulin glargine use because of its potential risk of mitogenicity but it proved to be true
only for human osteosarcoma cells Saos/B10. Outcomes of the studies performed on lines other than cancer cells and on animals did not
present any increased mitogenic activity nor mitogenic potency of insulin glargine in comparison to human insulin. (Pol J Endocrinol
2009; 60 (1): 34–39)
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Streszczenie
Celem leczenia cukrzycy jest uzyskanie i stałe utrzymywanie stanu zbliżonego do normoglikemii w celu zapobiegania powstawaniu
i progresji późnych powikłań naczyniowych. Aby uzyskać pełną kontrolę gikemii i poprawić jakość życia pacjentów chorujących na
cukrzycę, opracowano, dzięki wykorzystaniu technik rekombinacji DNA i zaawansowanych metod modyfikacji białek, wiele nowych
preparatów insulinowych — analogów insuliny. Ponieważ strukturalnie zmodyfikowana cząsteczka insuliny może różnić się od cząstecz-
ki ludzkiej insuliny nie tylko wpływem na metabolizm, ale również właściwościami mitogennymi, dlatego zwrócono uwagę na istnienie
ryzyka podwyższonej aktywności proliferacyjnej analogów insuliny. W celu dokładnej oceny profilu aktywności insulin analogowych
porównano je, zarówno w badaniach in vitro, jak i in vivo, z insuliną ludzką. Glargina okazała się być jedyną insuliną, która charakteryzuje się
znamiennie zwiększonym powinowactwem do receptora insulinopodobnego czynnika wzrostu 1 (IGF-1, insulin-like growth factor type 1).
Mimo że istniały kontrowersje dotyczące bezpieczeństwa stosowania glarginy z uwagi na ryzyko działania mitogennego, to okazało się
ono istotne jedynie w badaniach in vitro w odniesieniu do ludzkiej linii komórek kostniakomięsaka Saos/B10. Wyniki pozostałych badań
nie wykazały zwiększonej aktywności mitogennej lub potencjału mitogennego w porównaniu z insuliną ludzką.
(Endokrynol Pol 2009; 60 (1): 34–39)
Słowa kluczowe: insulina analogowa, glargine, mitogenność
Introduction
The purpose of this review is to summarize the outcomes
of performed up to date studies regarding the mitogenic
potency of insulin analogues. In response to human insu-
lin molecule structure modification, not only metabolic but
also supposedly mitogenic activity of insulin analogues
may be significantly altered, that is why the potentially
dangerous properties of these preparations have been
widely examined in both in vitro and in vivo studies.
In the year 1921, Canadian surgeon Frederic Ban-
ting, Charles Best a medical student, physiology pro-
fessor John J.R. Macleod, and James B. Collip a bioche-
mist discovered insulin by isolating the dog’s pancre-
atic internal extract. A year later insulin was successful-
ly injected a 14-year-old diabetic boy giving rise to the
era of insulin therapy that has lasted up to date. Insulin
discovery became a milestone in the history of diabetes
management, which turned out to be a landmark event
in twentieth-century medicine. Despite the fact that
more than 3500 years have past since the first notice
regarding diabetic symptoms described in Egyptian
papyrus dated 1550 years B.C., diabetes mellitus rema-
ins an incurable disease.
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The crystal structure of insulin was obtained for the
first time in the year 1926 by Jacob Abel, and in the mid
fifties the amino acid structure of the insulin particle
was defined by Frederick Sanger, initiating further stu-
dies devoted to the development of synthetic insulin.
Commercial animal (beef or pork) insulin production
begun in the year 1923 and these preparations were
used for more than half a century until the early 80s
when the development of genetic molecular techniqu-
es brought about new opportunities in insulin produc-
tion [1–4]. Since then recombinant DNA technology has
been used to develop insulin analogues with improved
kinetics profile and different absorption time in order
to more accurately approximate the endogenous insu-
lin secretion and improve metabolic control [5].
The effect of insulin on cells can be either metabolic
or mitogenic. The physiologic effects of insulin action
are not homogenous and differ in the time of the effect
appearance. Beside influencing glucose metabolism, in-
sulin exerts other biological functions taking part in such
complicated processes as proliferation, differentiation,
and cell apoptosis. Insulin also plays the role of growth
factor by, among other things, fulfilling a regulative role
in gene expression and protein biosynthesis. At low con-
centrations its intercellular activity leads to a very qu-
ick appearance of metabolic effects, whereas at higher
concentration the effects, including growth promotion
and development, occur with latency [6–8].
Insulin activity is driven through specific insulin re-
ceptors [6]. It also binds to structurally related recep-
tors for insulin-like growth factor type 1. The receptors
mentioned above present 80% homology in the B-sub-
unit. The insulin molecule and IGF-1 molecule itself
have 40–50 % homology [8–11].
Insulin affinity to the IGF-1 receptor is 1000-times
lower when compared to the insulin receptor and
1000-times lower when compared to the affinity presen-
ted by IGF-1. The IGF-1 receptor plays no important role
in insulin activity while physiological concentrations of
insulin occur. Stimulation of the IGF-1 receptor might be
important at the time when there are higher than phy-
siological concentrations of insulin observed or when the-
re are structurally changed insulin particles present, as it
appears in insulin analogues [8, 13].
Despite the improvement in insulin formulations,
its administration is still subcutaneous and has many
limitations. These are mainly the consequences of al-
ternations in the pharmacodynamic and pharmacoki-
netic properties of subcutaneously injected insulin that
enters systemic circulation and is distributed in the same
concentration to the liver as well as to all other peri-
pheral tissues instead of physiological, direct secretion
to the portal system, where 70% of insulin is retained.
Subcutaneous administration of human insulin is limi-
ted by the tendency to associate into dimmers and he-
xamers that cannot be absorbed through the capillary
wall and the multifarious insulin absorption rate from
subcutaneous tissue, dependent on the body area cho-
sen for injection, which makes it difficult to predict and
hampers the choice of adequate time of insulin injec-
tion before the meal ingestion.
Due to the introduction of insulin preparations to
common usage, diabetes is no longer considered a mor-
tal disease, and along with life expectancy, the dura-
tion of the disease has been prolonged. Unfortunately,
because of perennial hyperglycaemia, complications
occur, especially cardiovascular ones, being the cause
of disability and premature death emerging among
diabetic patients.
Therefore, in order to achieve improved glucose con-
trol scientists’ efforts lean toward inventing the most
physiological means of insulin administration, providing
constant basal insulin concentration and it’s prandial ele-
vation, because this is the only way to keep an optimal
metabolic control and simultaneously optimal flexibility
of treatment providing freedom to carry out daily activi-
ties and improving quality of life [6].
With the use of recombinant DNA technology the-
se were novel insulin molecules, insulin analogues with
altered physicochemical, biological, and pharmacody-
namic properties mimicking endogenous insulin action
designed to improve substantially glycaemic control.
The modification of the insulin molecule can either de-
lay or shorten its absorption time.
The preferred site for structural modification is the
B26-B30 region because it is not critical for insulin re-
ceptor recognition in order to modify the pharmacoki-
netic action of the insulin particle, but the c-terminal
end of the insulin B chain seems to be important in in-
sulin binding to the IGF-1 receptor [2, 6, 10].
The rapid-acting insulin analogues possess structu-
ral changes of the insulin particle causing instability of
hexamers after subcutaneous administration, and fast
conversion of hexamers into monomers that are absor-
bed, almost immediately, into the blood stream.
Rapid-acting analogues are represented by the fol-
lowing three 3 preparations: insulin lispro (Humalog®;
Eli Lilly), insulin aspart (NovoRapid®; Novo Nordisk),
and insulin glulisine (Apidra®; Sanofi-Aventis) [14–16].
Long-acting insulin analogues have the molecule of
insulin modified in a way to stabilize the hexamer com-
pound in order to absorb the preparation into the cir-
culation with a delay.
This group of insulin analogues is represented by the
following 2 preparations: insulin GlyA21ArgB31ArgB32
(Glargine, Lantus, HOE 901; Sanofi-Aventis) and insu-
lin LysB29 (N-tetradecanoyl) des (B30) (Detemier, Le-
vemir; Novo Nordisk) [15–18].
36
Glargine — mitogenic potency Katarzyna Żełobowska et al.
PR
A
C
E 
PO
G
LĄ
D
O
W
E
Because changing the insulin structure may funda-
mentally alter its metabolic as well as mitogenic poten-
cy, in recent years concern has been raised over the sa-
fety of insulin analogues, especially because an incre-
ase in the tumour promoting activity of insulin AspB10
in in vivo studies on animal model has been observed.
Mitogenic activity has also been observed in vitro stu-
dies performed on mice embryo pancreatic b-cell lines
and human breast cell lines.
AspB10 was produced by the modification of the
amino acid chain in the area responsible for IGF-1 re-
ceptor affinity, and when compared to human insulin
the insulin analogue was characterized by 3.5-times hi-
gher affinity to the insulin receptor and 9-times higher
affinity to the IGF-1 receptor as well as 9-times incre-
ased mitogenic potency. It has been noticed that AspB10
activates the insulin receptor as well as the IGF-1 re-
ceptor and presents increased mitogenic potency and
2–4-times increased metabolic activity when compared
with human insulin. It was initially thought that the
mitogenic effect of this insulin analogue is caused ma-
inly by higher affinity to the IGF-1 receptor. Confirma-
tion of this hypothesis was obtained from a study on
rat aortic smooth muscle cells where insulin AspB10 sti-
mulated the IGF-1 receptor with an affinity compara-
ble to the IGF-1 particle [24–26].
Insulin analogues provide diabetic patients with
advantageous therapeutic properties, but insulin admi-
nistration is a life-long treatment and any modification
of the insulin molecule can lead to an altered insulin
action profile and abnormal interaction with the insu-
lin and IGF-1 receptor, that is why it is very important
that the use of insulin analogues does not cause an in-
crease in safety risks.
Insulin analogues mitogenic potency
in vitro study
There has been a study performed by Kurtzhals et al.
aimed to  evaluate the mitogenic potential of 4 insulin
analogues (lispro, aspart, detemir, and glargine) with
the use of human osteosarcoma cells (Saos/B10) posses-
sing large amounts of IGF-1 receptors and small amo-
unts of insulin ones. In this in vitro study there was each
of the insulins’ affinity to the insulin and the IGF-1 re-
ceptor as well as dissociation time from the receptors
and mitogenic potency examined [22].
In comparison to human insulin, the affinity of insu-
lin lispro and insulin aspart to the insulin receptor was
slightly increased, and the affinity of long-acting prepa-
rations to the insulin receptor was decreased by half.
In contrast to insulin aspart, having an affinity to
the IGF-1 receptor similar to human insulin, insulin
lispro had a 1.5-times increased affinity.
When compared to human insulin, insulin glargine
had an affinity to the IGF-1 receptor 6.5-times increased
and insulin detemir had the affinity 15-times decreased.
The dissociation time from insulin receptor for both
insulin lispro and insulin aspart was comparable to that
of human insulin. When compared to human insulin
there was a faster dissociation of insulin glargine (2-ti-
mes) and insulin detemir (slightly) observed.
Despite the increased affinity of insulin lispro to the
IGF-1 receptor, when compared to human insulin, sti-
mulation of growth processes by insulin lispro and in-
sulin aspart was decreased but mitogenic potency of
those preparations was the same.
Glargine mitogenic action proved to be 8-times in-
creased when compared to human insulin, while insu-
lin detemir presented 250-times decreased mitogenic
potency [22].
Insulin glargine was the only one of the mentioned
above preparations that presented a significantly incre-
ased affinity to the IGF-1 receptor. However, based on
recently performed in vitro studies regarding different
cell lines, the increased mitogenic potency was obse-
rved only in the studies regarding human osteosarco-
ma cells (Saos/B10) [28].
Insulin glargine
Glargine (Lantus, HOE 901) is, until now, the only long-
acting insulin analogue having no pronounced plasma
peak that after a single daily injection exerts a glucose
lowering effect for 24 hours. Production of the insulin
is performed with the use of a DNA recombination
method and results from elongation of the c-terminal
end of the insulin B chain by adding 2 arginine residues
at positions 31 and 32 and substituting asparagine resi-
due with glycine in the A chain at position 21 [29–31].
Insulin glargine mitogenic potency
in vitro studies
Bahr et al. performed one of the first in vitro studies
with the use of cardiomyoblasts (H9C2) and rat cardio-
myocytes characterized by over-expression of IGF-1 re-
ceptors and simultaneously low expression of insulin
receptors. There was no difference in activity toward
cardiomyocytes as well as maximum metabolic activity
between insulin glargine and human insulin noticed in
this study [32].
To asses the potent mitogenic activity of insulin glar-
gine through insulin receptor signalling, Bert et al. con-
ducted a study on transfected rat fibroblasts presenting
over-expression of human insulin receptor and low
expression of IGF-1 receptor. There was a similarity
between human insulin and insulin glargine in terms
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of receptor affinity, activity of early signal transduction,
and mitogenic action observed. However, the higher
number of insulin receptors could mask the mitogenic
potency mediated through the IGF-1 receptor [28].
Kurtzhal et al. compared insulin glargine to human
insulin in order to estimate the affinity to the IGF-1 re-
ceptor and the mitogenic potency in a study on puri-
fied receptors from transfected cells lines with the use
of the human osteosarcoma cell Saos/B10; an increased
insulin glargine mitogenic potency and IGF-1 receptor
affinity was observed [22].
Skeletal muscle cells obtained from type 2 diabetic
patients and from healthy people were used in the stu-
dy by Ciaraldi et al. to assess the affinity of insulin glar-
gine and human insulin to insulin receptor and to IGF-
1 receptor as well as the supposed mitogenic and meta-
bolic potency of insulin glargine in comparison to hu-
man insulin and IGF-1. Similarly, as was proven in the
studies described above, the mitogenic potency and
metabolic activity of insulin glargine and human insu-
lin were comparable [33, 34].
The main causes of mortality in the group of diabe-
tic patients are cardiovascular complications. Taking
into account the information from the above studies
indicating increased affinity of insulin glargine to IGF-1
receptor and, additionally, a tendency toward the use
of increasing insulin doses among type 2 diabetes pa-
tients, mainly due to insulin resistance, it is important
to consider whether treatment with high doses of insu-
lin is a safe therapy.
Endothelium cells and smooth muscle cells of blood
vessel walls express both insulin and IGF-1 receptors.
Throughout the years there has been an ongoing deba-
te regarding the role of elevated insulin concentration
as a cardiovascular independent risk factor. Nowadays,
the idea of the positive influence of insulin therapy on
the vascular system through, inter alia, improvement
of lipid control, endothelium function, and anti-inflam-
mation properties predominates. Endothelium dysfunc-
tion and loss of endothelium-dependent vasodilatation
are considered the most significant factors in the pa-
thogenesis of diabetic angiopathy and atherosclerosis
progression [35–42].
Chisalita et al. evaluated insulin receptors and IGF-1
receptors of human endothelium cells localized in small
and large blood vessels in terms of gene expression, li-
gand binding potency, receptor activation, and biolo-
gical effect caused by insulin glargine and IGF-1.
The outcomes showed that the IGF-1 receptor gene
expression and ligand binding were increased in com-
parison to insulin receptor. The study indicated that
insulin glargine, in comparison to human insulin, had
a 10-times higher affinity to the IGF-1 receptor, but this
feature was presented only in the study performed on
human osteosarcoma cells where insulin glargine affi-
nity to the IGF-1 receptor was 6-times higher [13].
In recent communications, proliferation and apop-
tosis phenomenon have been indicated to have great
significance in the development and stability of athe-
rosclerosis plaque.
Staiger et al. estimated the influence of human insulin
and insulin glargine on the proliferation and apoptosis of
human endothelium cells and human coronary artery
smooth muscle cells and proved that neither of the in-
sulins stimulates DNA synthesis or augments apopto-
sis in the coronary artery cells. It must be noted that the
studied coronary artery cells were obtained from heal-
thy people, and it is possible that people with coronary
artery disease could present different outcomes [46, 47].
Because insulin glargine, compared to human insulin,
has a 6-times higher affinity to the IGF-1 receptor, it is re-
cognized as a breast cancer tumour pathogenesis element.
Staiger et al. studied the mitogenic potency of insulin glar-
gine in comparison to human insulin on human breast
cancer cell lines (MCF-7) and on normal human epithelial
breast cell lines (MCF-10). There was no significant diffe-
rence found in the mitogenic potency between insulin glar-
gine and human insulin neither in normal epithelial cell
lines nor in human breast cancer cell lines. This was the
first study performed on carcinoma cell lines since the stu-
dy on the human osteosarcoma cells [47].
There has been a suggestion that the rate of amount
of receptors for IGF-1 to amount of insulin receptors
has a key meaning for cell sensitivity to insulin mitoge-
nic action. Defected cells that have undergone mali-
gnant transformation, characterized by over-expression
of IGF-1 receptor and a low amount of insulin recep-
tors, present an elevated mitogenic response to insulin
glargine, and human osteosarcoma cells Saos/B10 can
serve as an example of such a situation [48].
Insulin glargine mitogenic potency
in vivo studies
A preclinical, toxicological study on mice and rats was
performed by Stammberger et al. in order to assess the
carcinogenic potency of insulin glargine. There was no
higher rate of breast cancer nor any other carcinogenic
effect observed in the rodents examined in the study [49].
There was no direct negative influence of insulin
glargine observed on the reproductive system or foetus
growth in the study of Hoffman et al. conducted in rats
and rabbits. When high doses of insulin glargine were
administered, a higher number of miscarriages was ob-
served among the studied animals, but it was hypogly-
caemia not the carcinogenic effect of insulin glargine
that was thought to be the most probable cause of the
phenomenon [50].
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Despite the outcomes of the studies, suggesting that
human insulin and insulin glargine exert their mitoge-
nic action through the IGF-1 receptor, it is unlikely that
therapeutic concentrations of human insulin and insu-
lin glargine in vivo may lead to mitogenesis of untrans-
formed cells trough IGF-1 receptor activation.
Moreover, there is a body of evidence that insulin
receptor might be involved in evoking the mitogenic
effect. In accordance with the observations of Shymko
et al., confirmed by Hansen et al., the main determi-
nant of selectivity for metabolic or mitogenic signal
transduction is the time of insulin to insulin receptor
binding [27, 51, 52] . Insulin analogues that have longer
dissociation time than native insulin are characterized
by increased mitogenicity. A slightly faster dissociation
time of insulin glargine in comparison with human in-
sulin was observed in the majority of studies. Compa-
ring insulin glargine with insulin AspB10 presenting in-
creased mitogenic activity, the latter was characterized
by a significantly slower dissociation and prolonged
phosphorylation of intercellular protein. It is worth
noting that the long action of insulin glargine is con-
nected to alternations in the pharmacokinetic proper-
ties of the insulin particle, not to prolonged binding to
the receptor [26, 28, 51–55].
Conclusions
Insulin glargine has raised special scientific interest be-
cause of its potential risk of mitogenicity, but this pro-
ved to be true only for human osteosarcoma cells Saos/
/B10. The outcomes of studies performed on cell lines
other than cancer and on animals do not present incre-
ased mitogenic activity or mitogenic potency of insulin
glargine in comparison to human insulin [49, 56].
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